Cargando…
Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
Immune checkpoint blockade (ICB) therapy for cancer has achieved great success both in clinical results and on the market. At the same time, success drives more attention from scientists to improve it. However, only a small portion of patients are responsive to this therapy, and it comes with a uniq...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142459/ https://www.ncbi.nlm.nih.gov/pubmed/37106400 http://dx.doi.org/10.1186/s40779-023-00455-x |